Upfront Cost Guidance Limited in US Guidelines - Summary - MDSpire
Advertisement
Upfront Cost Guidance Limited in US Guidelines
Although most large US-based medical societies in a cross-sectional study explicitly suggested considering economic or resource use–related evidence during guideline development, only 3.8% of individual recommendations included that information in the recommendation statement itself.
To evaluate the incorporation of economic and resource use-related guidance in US clinical practice guidelines.
Approach:
Study Design: Cross-sectional study analyzing 309 clinical practice guideline documents from 23 large US-based medical societies issued between 2019 and 2023.
Data Collection: Guidelines were identified through the ECRI Guidelines Trust, and economic-related terms were used to assess recommendations.
Analysis: The study assessed the presence of economic guidance in both upfront recommendation statements and narrative discussions.
Key Findings:
Only 3.8% of recommendations included an upfront economic or resource use-related statement.
76% of guideline documents contained at least one recommendation with a narrative discussion of economic evidence.
Recommendations from primary care societies were nearly 13 times more likely to include upfront economic statements compared to specialty societies.
Across all 7,582 recommendations, 1,706, or 22.5%, included a narrative discussion of economic or resource use-related evidence.
Interpretation:
Despite an increase in attention to economic considerations in guideline development, they are infrequently included in individual recommendations.
Limitations:
The assessment of economic guidance was based on a broad composite measure and did not evaluate the quality or clinical usefulness of the guidance.
The sample was limited to guidelines in the ECRI Guidelines Trust and may not represent all guidelines from the included societies.
Conclusion:
Higher quality health economic evidence and explicit consideration of such evidence may improve the incorporation of economic guidance in clinical practice guidelines.
Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer, and mortality across three large cohorts.
Heart rate monitoring and atrial fibrillation detection had the strongest supporting evidence, but investigators found limited evidence for broader outpatient self-monitoring applications.
